Repatha (evolocumab)
pCPA File Number:
22741
Negotiation Status:
Under consideration for negotiation
Indication(s):
Primary hyperlipidemia
Sponsor/Manufacturer:
Amgen Canada Inc.
CDA-AMC Project Number:
SR0821-000
pCPA Engagement Letter Issued:
Not Applicable
Negotiation Process Concluded:
Not Applicable